Key Highlights
- CNS Pharmaceuticals (NASDAQ:CNSP) reported a third-quarter net loss of USD 2.5 million, down 22.3% from USD 3.2 million, or USD 0.24 a share against USD 5.76 a year earlier.
- Research and development spending fell 59.5% to USD 0.9 million as the Berubicin trial closed out, while general and administrative costs rose 68.1% to USD 1.8 million.
- Cash was about USD 17.2 million at September 30, 2026, with a Working Capital surplus of USD 15.7 million after a USD 22.5 million private Placement in May.
- Management plans to acquire rights to a new asset by the end of 2026 and is exploring out-licensing for legacy Assets TPI 287 and Berubicin.
Lower Trial Spending Trims the Quarterly Loss
CNS Pharmaceuticals (NASDAQ:CNSP) is a Nevada-incorporated biotechnology company that was built around Berubicin, a candidate for glioblastoma multiforme, and is now repositioning. Its quarterly report, filed November 16, 2026, shows operating expenses of USD 2.7 million for the quarter ended September 30, 2026, down 18.1% from USD 3.3 million. Research and Development fell USD 1.3 million, mostly because Berubicin enrollment and treatment are complete, and Manufacturing costs for TPI 287 were about USD 0.5 million lower. Interest income of USD 0.17 million also helped, as higher Money Market balances lifted total other income to USD 0.17 million from USD 0.04 million a year earlier.
Strategy Shift Raises Overhead and the Funding Question
Since the first quarter, a new executive team has pursued assets in neurology, oncology or rare diseases rather than a single glioblastoma focus. That pushed general and administrative expense up USD 0.7 million, with consulting up USD 0.5 million for Business development and headcount costs up USD 0.4 million. Nine-month net loss was USD 10.0 million, or USD 1.65 a share, compared with USD 9.9 million, or USD 25.60 a share, a year earlier. Per-share figures reflect a 1-for-12 reverse split effected in July 2025 and include pre-funded warrants. For the nine months, general and administrative expense rose USD 1.3 million to USD 4.7 million, with personnel up USD 0.8 million and recruiting up USD 0.3 million, while research and development fell USD 1.0 million to USD 5.6 million.
Cash Runway Depends on Finding and Funding a New Asset
Nine-month operating cash outflow was about USD 11.0 million, while financing brought in about USD 21.0 million, including the May 2026 placement of 650,000 shares at USD 2.30 and pre-funded warrants over 9,143,479 shares. The company says that money plus existing cash should fund planned operations beyond twelve months. It has no financing commitments, will likely need more Equity or debt, and warns it may cease operations if its plan fails. The company also sold 178,933 shares through its at-the-market program during the reporting period for net proceeds of about USD 0.5 million. Common shares outstanding were 1,475,699 as of November 15, 2026.
Where Things Stand
Yes, spending is falling, but only because the lead trial has closed out. CNS Pharmaceuticals (NASDAQ:CNSP) lost USD 2.5 million in the quarter, and nine-month operating cash burn of USD 11.0 million is covered by USD 17.2 million of cash. The company has not yet secured a replacement asset, so costs will change once one is licensed. Watch for an Acquisition or licensing announcement by year-end, any out-licensing of Berubicin or TPI 287, and further capital raises through the at-the-market program or new offerings, since the company says its work will need significant additional capital.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...